Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Immix Biopharma Inc(IMMX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for IMMX
09/17/2026: IMMX (4-star) is a SELL. SELL for 2 days. Simulated Profits (5.11%). Updated daily EoD!
Immix Biopharma is a clinical-stage biotechnology company focused on its proprietary SMARxT platform for targeted oncology therapies. The firm's main strength lies in its specialized technology designed to improve drug safety, which represents its primary growth opportunity as it advances its lead candidate, IMX-110. However, the company faces substantial execution, financial, and competitive risks, as it lacks current revenue and remains heavily dependent on capital raises to fund ongoing research. The stock is best suited for growth-oriented investors with a high risk tolerance who are looking for speculative exposure to biotech innovation. Key developments to monitor include clinical data readouts and potential partnership announcements.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a high-risk/high-reward speculative play dependent on clinical trial outcomes. |
| Momentum investor | Mixed fit | Momentum may be driven by clinical trial news or trial results rather than valuation. |
| Value investor | Weak fit | The company lacks current earnings or traditional value metrics. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses entirely on cash-intensive R&D. |
| Low-risk investor | Weak fit | The high volatility and clinical failure risk are unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is subject to significant fluctuations based on clinical trial news. |
| Valuation risk | High | Valuation is highly speculative and disconnected from current revenue. |
| Competition risk | High | Large-cap biotech firms with superior resources compete in the same target oncology markets. |
| Business quality | Medium | The business model is in an early stage with no proven commercial success. |
| Dividend income | Low / none | There is no dividend income and none is expected in the near term. |
| Execution risk | High | Success relies heavily on meeting complex clinical and regulatory endpoints. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 61.45% | Avg. Invested days 26 | Today’s Advisory SELL |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 852.75M USD | Price to earnings Ratio - | 1Y Target Price 22.52 |
Price to earnings Ratio - | 1Y Target Price 22.52 | ||
Volume (30-day avg) 1.5M shares | Beta 0.2 | 52 Weeks Range 1.98 - 15.10 | Updated Date 09/17/2026 |
52 Weeks Range 1.98 - 15.10 | Updated Date 09/17/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.88 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Advancing drug candidates like IMX-110 through clinical trials. | The company does not currently sell products; it seeks to create value by proving technology efficacy. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 623.07M | Price to Sales(TTM) - |
Enterprise Value 623.07M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.37 | Shares Outstanding 71.54M | Shares Floating 56.17M |
Shares Outstanding 71.54M | Shares Floating 56.17M | ||
Percent Insiders 17.13 | Percent Institutions 78.92 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Immix Biopharma Inc
Exchange NASDAQ | Headquarters Los Angeles, CA, United States | ||
IPO Launch date 2021-12-16 | Co-Founder, CEO, Chief Scientific Officer & Chairman Dr. Ilya Rachman M.B.A., M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 21 | Website https://www.immixbio.com |
Full time employees 21 | Website https://www.immixbio.com | ||
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.